Cost of hospital management of Clostridium difficile infection in United States-a meta-analysis and modelling study

BMC Infectious Diseases

Volumn 16, Issue 1, 2016, Pages

  Zhang, Shanshan ^a,b   Palazuelos Munoz, Sarah ^c   Balsells, Evelyn M ^a   Nair, Harish ^a   Chit, Ayman ^c,d   Kyaw, Moe H ^c  

^a UNIVERSITY OF EDINBURGH   (United Kingdom)

^b PEKING UNIVERSITY SCHOOL AND HOSPITAL OF STOMATOLOGY   (China)

^c SANOFI PASTEUR   (France)

^d UNIVERSITY OF TORONTO   (Canada)

Author keywords

Clostridium difficile; Economic analysis; Meta analysis; Systematic review

Indexed keywords

ARTICLE; CASE MANAGEMENT; CLOSTRIDIUM DIFFICILE INFECTION; COMORBIDITY; FINANCIAL MANAGEMENT; HEALTH CARE FACILITY; HEALTH CARE SYSTEM; HEALTH ECONOMICS; HOSPITAL COST; HOSPITAL MANAGEMENT; HOSPITAL PATIENT; HUMAN; LENGTH OF STAY; LONG TERM CARE; META ANALYSIS (TOPIC); MONTE CARLO METHOD; RECURRENT INFECTION; RESOURCE ALLOCATION; UNITED STATES; CLOSTRIDIUM INFECTIONS; COST; ECONOMICS; FACTUAL DATABASE; HOSPITALIZATION; META ANALYSIS;

CLOSTRIDIUM INFECTIONS; COSTS AND COST ANALYSIS; DATABASES, FACTUAL; HOSPITAL COSTS; HOSPITALIZATION; HUMANS; LENGTH OF STAY; UNITED STATES;

EID: 84983605323     PISSN: None     EISSN: 14712334     Source Type: Journal    
DOI: 10.1186/s12879-016-1786-6     Document Type: Article

References (73)

1. Crobach M, Dekkers O, Wilcox M, Kuijper E. European Society of Clinical Microbiology and Infectious Diseases (ESCMID): data review and recommendations for diagnosing Clostridium difficile-infection (CDI). Clin Microbiol Infect. 2009;15(12):1053-66.
2. Dubberke ER, Carling P, Carrico R, et al. Strategies to prevent clostridium difficile infections in acute care hospitals: 2014 update. Infect Control Hosp Epidemiol. 2014;35(SUPPL2):628-45.
3. Mylonakis E, Ryan E, Calderwood S. Clostridium difficile-Associated diarrhea: A review. Arch Intern Med. 2001;161(4):525-33.
4. Rubin M, Bodenstein L, Kent K. Severe Clostridium difficile colitis. Dis Colon Rectum. 1995;38(4):350-4.
5. Triadafilopoulos G, Hallstone AE. Acute abdomen as the first presentation of pseudomembranous colitis. Gastroenterology. 1991;101(3):685-91.
6. Sanchez T, Brooks J, Sullivan P, et al. Bacterial diarrhea in persons with HIV infection, United States, 1992-2002. Clin Infect Dis. 2005;41(11):1621-7.
7. Bilgrami S, Feingold J, Dorsky D, et al. Incidence and outcome of Clostridium difficile infection following autologous peripheral blood stem cell transplantation. Bone Marrow Transplant. 1999;23(10):1039-42.
8. Barbut F, Corthier G, Charpak Y, et al. Prevalence and pathogenicity of Clostridium difficile in hospitalized patients. A French multicenter study. Arch Intern Med. 1996;156(13):1449-54.
9. Cohen S, Gerding D, Johnson S, et al. Clinical practice guidelines for Clostridium difficile infection in adults: 2010 update by the society for healthcare epidemiology of America (SHEA) and the infectious diseases society of America (IDSA). Infect Control Hosp Epidemiol. 2010;31(5):431-55.
10. Bignardi G. Risk factors for Clostridium difficile infection. J Hosp Infect. 1998;40(1):1-15.
11. Aseeri M, Schroeder T, Kramer J, Zackula R. Gastric acid suppression by proton pump inhibitors as a risk factor for clostridium difficile-associated diarrhea in hospitalized patients. Am J Gastroenterol. 2008;103(9):2308-13.
12. Bauer M, Notermans D, van Benthem B, et al. Clostridium difficile infection in Europe: a hospital-based survey. Lancet. 2011;377(9759):63-73.
13. Dubberke ER, Wertheimer AI. Review of current literature on the economic burden of Clostridium difficile infection. Infect Control Hosp Epidemiol. 2009;30(1):57-66.
14. Dubberke ER, Olsen MA. Burden of Clostridium difficile on the healthcare system. Clin Infect Dis. 2012;55 Suppl 2:S88-92.
15. Gabriel L, Beriot-Mathiot A. Hospitalization stay and costs attributable to Clostridium difficile infection: a critical review. J Hosp Infect. 2014;88(1):12-21.
16. Ghantoji SS, Sail K, Lairson DR, Dupont HL, Garey KW. Economic healthcare costs of Clostridium difficile infection: a systematic review. J Hosp Infect. 2010;74(4):309-18.
17. Zimlichman E, Henderson D, Tamir O, et al. Health care-associated infections: a meta-analysis of costs and financial impact on the US health care system. JAMA Intern Med. 2013;173(22):2039-46.
18. Johnson S. Recurrent Clostridium difficile infection: A review of risk factors, treatments, and outcomes. J Infect. 2009;58(6):403-10.
19. Mergenhagen KA, Wojciechowski AL, Paladino JA. A review of the economics of treating Clostridium difficile infection. Pharmacoeconomics. 2014;32(7):639-50.
20. Wiegand PN, Nathwani D, Wilcox MH, Stephens J, Shelbaya A, Haider S. Clinical and economic burden of Clostridium difficile infection in Europe: a systematic review of healthcare-facility-acquired infection. J Hosp Infect. 2012;81(1):1-14.
21. Bouza E. Consequences of Clostridium difficile infection: understanding the healthcare burden. Clin Microbiol Infect. 2012;18 Suppl 6:5-12.
22. [Accessed November 9, 2015] Cost-to-charge ratio files. Healthcare Cost and Utilization Project Web site. http://www.hcup-us.ahrq.gov/db/state/costtocharge.jsp.
23. Jha A, Chan D, Ridgway A, Franz C, Bates DW. Improving Safety And Eliminating Redundant Tests: Cutting Costs In U.S. Hospitals. Health Aff. 2009;28(5):1475-84.
24. Lessa FC, Winston LG, McDonald LC, Emerging Infections Program C. difficile Surveillance Team. Burden of Clostridium difficile infection in the United States. N Engl J Med. 2015;372(24):2369-70.
25. Hernández EB, Nair H, Campbell H, Kyaw M. Global burden of healthcare- and community- C. difficile-associated disease-systematic review and meta-analysis (unpublisehd report). University of Edinburgh; 2015.
26. Nanwa N, Kendzerska T, Krahn M, et al. The economic impact of Clostridium difficile infection: a systematic review. Am J Gastroenterol. 2015;110(4):511-9.
27. Ali M, Ananthakrishnan AN, Ahmad S, Kumar N, Kumar G, Saeian K. Clostridium difficile infection in hospitalized liver transplant patients: a nationwide analysis. Liver Transpl. 2012;18(8):972-8.
28. Ananthakrishnan AN, Mcginley EL, Binion DG. Excess hospitalisation burden associated with Clostridium difficile in patients with inflammatory bowel disease. Gut. 2008;57(2):205-10.
29. Arora V, Kachroo S, Ghantoji SS, Dupont HL, Garey KW. High Horn's index score predicts poor outcomes in patients with Clostridium difficile infection. J Hosp Infect. 2011;79(1):23-6.
30. Bajaj JS, Ananthakrishnan AN, Hafeezullah M, et al. Clostridium difficile is associated with poor outcomes in patients with cirrhosis: A national and tertiary center perspective. Am J Gastroenterol. 2010;105(1):106-13.
31. Campbell R, Dean B, Nathanson B, Haidar T, Strauss M, Thomas S. Length of stay and hospital costs among high-risk patients with hospital-origin Clostridium difficile-associated diarrhea. J Med Econ. 2013;16(3):440-8.
32. Damle RN, Cherng NB, Flahive JM, et al. Clostridium difficile infection after colorectal surgery: a rare but costly complication. J Gastrointest Surg. 2014;18(10):1804-11.
33. Dubberke ER, Reske KA, Olsen MA, McDonald LC, Fraser VJ. Short- and long-term attributable costs of Clostridium difficile-associated disease in nonsurgical inpatients. Clin Infect Dis. 2008;46(4):497-504.
34. Dubberke ER, Schaefer E, Reske KA, Zilberberg M, Hollenbeak CS, Olsen MA. Attributable inpatient costs of recurrent Clostridium difficile infections. Infect Control Hosp Epidemiol. 2014;35(11):1400-7.
35. Egorova NN, Siracuse JJ, Mckinsey JF, Nowygrod R. Trend, risk factors, and costs of clostridium difficile infections in vascular surgery. Ann Vasc Surg. 2015;29(4):792-800.
36. Flagg A, Koch CG, Schiltz N, et al. Analysis of Clostridium difficile infections after cardiac surgery: epidemiologic and economic implications from national data. J Thorac Cardiovasc Surg. 2014;148(5):2404-9.
37. Fuller RL, McCullough EC, Bao MZ, Averill RF. Estimating the Costs of Potentially Preventable Hospital Acquired Complications. Health Care Financ Rev. 2009;30(4):17-32.
38. Glance LG, Stone PW, Mukamel DB, Dick AW. Increases in mortality, length of stay, and cost associated with hospital-acquired infections in trauma patients. Arch Surg. 2011;146(7):794-801.
39. Jiang Y, Viner-Brown S, Baier R. Burden of hospital-onset Clostridium difficile infection in patients discharged from Rhode Island hospitals, 2010-2011: application of present on admission indicators. Infect Control Hosp Epidemiol. 2013;34(7):700-8.
40. Kim SP, Shah ND, Karnes RJ, et al. The implications of hospital acquired adverse events on mortality, length of stay and costs for patients undergoing radical cystectomy for bladder cancer. J Urol. 2012;187(6):2011-7.
41. Kuntz JL, Johnson ES, Raebel MA, et al. Epidemiology and healthcare costs of incident Clostridium difficile infections identified in the outpatient healthcare setting. Infect Control Hosp Epidemiol. 2012;33(10):1031-8.
42. Lagu T, Stefan MS, Haessler S, et al. The impact of hospital-onset Clostridium difficile infection on outcomes of hospitalized patients with sepsis. J Hosp Med (Online). 2014;9(7):411-7.
43. Lemaire A, Dombrovskiy V, Batsides G, et al. The Effect of Clostridium difficile Infection on Cardiac Surgery Outcomes. Surg Infect (Larchmt). 2015;16(1):24-8.
44. Lawrence SJ, Puzniak LA, Shadel BN, Gillespie KN, Kollef MH, Mundy LM. Clostridium difficile in the intensive care unit: epidemiology, costs, and colonization pressure. Infect Control Hosp Epidemiol. 2007;28(2):123-30.
45. Lesperance K, Causey MW, Spencer M, Steele SR. The morbidity of Clostridium difficile infection after elective colonic resection-results from a national population database. Am J Surg. 2011;201(2):141-8.
46. Lipp MJ, Nero DC, Callahan MA. Impact of hospital-acquired Clostridium difficile. J Gastroenterol Hepatol. 2012;27(11):1733-7.
47. Maltenfort MG, Rasouli MR, Morrison TA, Parvizi J. Clostridium difficile colitis in patients undergoing lower-extremity arthroplasty: rare infection with major impact. Clin Orthop Relat Res. 2013;471(10):3178-85.
48. Mcglone SM, Bailey RR, Zimmer SM, et al. The economic burden of Clostridium difficile. Clin Microbiol Infect. 2012;18(3):282-9.
49. Nguyen GC, Kaplan GG, Harris ML, Brant SR. A national survey of the prevalence and impact of Clostridium difficile infection among hospitalized inflammatory bowel disease patients. Am J Gastroenterol. 2008;103(6):1443-50.
50. Nylund CM, Goudie A, Garza JM, Fairbrother G, Cohen MB. Clostridium difficile infection in hospitalized children in the United States. Arch Pediatr Adolesc Med. 2011;165(5):451-7.
51. O'Brien JA, Lahue BJ, Caro JJ, Davidson DM. The emerging infectious challenge of clostridium difficile-associated disease in Massachusetts hospitals: clinical and economic consequences. Infect Control Hosp Epidemiol. 2007;28(11):1219-27.
52. Pakyz A, Carroll NV, Harpe SE, Oinonen M, Polk RE. Economic impact of Clostridium difficile infection in a multihospital cohort of academic health centers. Pharmacotherapy: J Hum Pharmacol Drug Ther. 2011;31(6):546-51.
53. Pant C, Anderson MP, O'Connor JA, Marshall CM, Deshpande A, Sferra TJ. Association of Clostridium difficile infection with outcomes of hospitalized solid organ transplant recipients: results from the 2009 Nationwide Inpatient Sample database. Transpl Infect Dis. 2012;14(5):540-7.
54. Pant C, Deshpande A, Anderson MP, Sferra TJ. Clostridium difficile infection is associated with poor outcomes in end-stage renal disease. J Investig Med. 2012;60(2):529-32.
55. Pant C, Anderson MP, Deshpande A, et al. Health care burden of Clostridium difficile infection in hospitalized children with inflammatory bowel disease. Inflamm Bowel Dis. 2013;19(5):1080-5.
56. Peery AF, Dellon ES, Lund J, et al. Burden of gastrointestinal disease in the United States: 2012 update. Gastroenterol. 2012;143(5):1179-87. e1-3.
57. Quimbo RA, Palli SR, Singer J, Strauss ME, Thomas SM. Burden of Clostridium difficile-associated diarrhea among hospitalized patients at high risk of recurrent infection. J Clin Outcomes Manag. 2013;20(12):544-54.
58. Reed IJF, Edris BA, Eid S, Molitoris A. Clostridium difficile: the new epidemic. Int J Infect Dis. 2009;7(1):1-5.
59. Sammons JS, Localio R, Xiao R, Coffin SE, Zaoutis T. Clostridium difficile infection is associated with increased risk of death and prolonged hospitalization in children. Clin Infect Dis. 2013;57(1):1-8.
60. Singal AK, Salameh H, Kamath PS. Prevalence and in-hospital mortality trends of infections among patients with cirrhosis: a nationwide study of hospitalised patients in the United States. Aliment Pharmacol Ther. 2014;40(1):105-12.
61. Song X, Bartlett JG, Speck K, Naegeli A, Carroll K, Perl TM. Rising economic impact of clostridium difficile-associated disease in adult hospitalized patient population. Infect Control Hosp Epidemiol. 2008;29(9):823-8.
62. Stewart DB, Hollenbeak CS. Clostridium difficile colitis: factors associated with outcome and assessment of mortality at a national level. J Gastrointest Surg. 2011;15(9):1548-55.
63. Tabak YP, Zilberberg MD, Johannes RS, Sun X, McDonald LC. Attributable burden of hospital-onset Clostridium difficile infection: a propensity score matching study. Infect Control Hosp Epidemiol. 2013;34(6):588-96.
64. Verlee KE, Finks JL, Wilkins MJ, Wells EV. Michigan Clostridium difficile hospital discharges: frequency, mortality, and charges, 2002-2008. Public Health Rep. 2012;127(1):62-71.
65. Wang L, Stewart DB. Increasing hospital costs for Clostridium difficile colitis: type of hospital matters. Surgery. 2011;150(4):727-35.
66. Wilson MZ, Hollenbeak CS, Stewart DB. Impact of Clostridium difficile colitis following closure of a diverting loop ileostomy: results of a matched cohort study. Colorectal Dis. 2013;15(8):974-81.
67. Zerey M, Paton BL, Lincourt AE, Gersin KS, Kercher KW, Heniford BT. The burden of Clostridium difficile in surgical patients in the United States. Surg Infect (Larchmt). 2007;8(6):557-66.
68. Zilberberg MD, Nathanson BH, Sadigov S, Higgins TL, Kollef MH, Shorr AF. Epidemiology and outcomes of clostridium difficile-associated disease among patients on prolonged acute mechanical ventilation. Chest. 2009;136(3):752-8.
69. Kyne L, Hamel M, Polavaram R, Kelly C. Health care costs and mortality associated with nosocomial diarrhea due to Clostridium difficile. Clin Infect Dis. 2002;34(3):346-53.
70. de Angelis G, Murthy AR, Beyersmann J, Harbarth S. Estimating the impact of healthcare-associated infections on length of stay and costs. Clin Microbiol Infect. 2010;16(12):1729-35.
71. Dubberke E, Carling P, Carrico R, et al. Strategies to Prevent Clostridium difficile Infections in Acute Care Hospitals: 2014 Update. Infect Control Hosp Epidemiol. 2014;35(6):628-45.
72. Bruyn Gd, Foglia G, Saleh J, Workman D, Pollak R, Gesser R. A phase II study of the safety and immunogenicity of different vaccination schedules of a candidate clostridium difficile toxoid vaccine: vaccination schedule selection for phase III 24th Annual Meeting of the European Congress of Clinical Microbiology and Infectious Diseases (ECCMID); 2014; Barcelona, Spain; 2014.
73. Foglia G, Shah S, Luxemburger C, Pietrobon PJF. Clostridium difficile: Development of a novel candidate vaccine. Vaccine. 2012;30(29):4307-9.